Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mailuotong Keli is a Traditional Chinese Medicine (TCM) granule formulation developed as an in-hospital preparation by the Foshan Maternity & Child Healthcare Hospital. It is primarily indicated for the treatment of coronary heart disease (CHD) and asymptomatic myocardial ischemia (SMI). The formulation is designed to promote blood circulation, resolve blood stasis, and unblock the meridians (vessels), which are key therapeutic principles in TCM for managing cardiovascular conditions. Clinical utilization within the hospital setting has focused on its ability to improve myocardial blood supply and reduce the frequency of ischemic episodes in patients with chronic stable angina or silent ischemia. As an in-hospital preparation, its use is typically restricted to the developing institution and its affiliated medical network under specific regulatory frameworks in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mailuotong keli.